Changes to Primary Endpoints of Cancer Trials Are Not Being Disclosed in Manuscripts
Changes to primary endpoints of phase 3 cancer trials may be common and underreported, a study suggests.
Changes to primary endpoints of phase 3 cancer trials may be common and underreported, a study suggests.
At a SITC summit, stakeholders identified administrative, staffing, and other barriers that impede progress in clinical cancer research.
New data highlight the high cost of targeted oral anticancer medicines for patients with Medicare Part D coverage.
New research suggests aspirin may lower the risk for gastric adenocarcinoma in women but not in men.